PDF(Pubmed)
Abstract：
Buprenorphine is an effective and safe treatment for opioid use disorder, but the requirement for moderate opioid withdrawal symptoms to emerge prior to initiation is a significant treatment barrier.
We report on two cases of hospitalized patients with severe, active opioid use disorder, in which we initiated treatment with transdermal buprenorphine over 48 h, followed by the administration of a single dose of sublingual buprenorphine/naloxone and then extended-release subcutaneous buprenorphine. The patients did not experience precipitated withdrawal and only had mild withdrawal symptoms.
This provides preliminary evidence for a rapid induction strategy that may improve tolerability, caregiver burden, and treatment retention as compared to previous induction strategies.
We report on two cases of hospitalized patients with severe, active opioid use disorder, in which we initiated treatment with transdermal buprenorphine over 48 h, followed by the administration of a single dose of sublingual buprenorphine/naloxone and then extended-release subcutaneous buprenorphine. The patients did not experience precipitated withdrawal and only had mild withdrawal symptoms.
This provides preliminary evidence for a rapid induction strategy that may improve tolerability, caregiver burden, and treatment retention as compared to previous induction strategies.
摘要：
背景：丁丙诺啡是阿片类药物使用障碍的有效且安全的治疗方法，但在开始治疗前需要出现中度阿片类药物戒断症状是一个重要的治疗障碍.
方法：我们报告2例重症住院患者，活跃的阿片类药物使用障碍，其中我们开始使用经皮丁丙诺啡治疗超过48小时，然后给予单剂量舌下丁丙诺啡/纳洛酮，然后皮下缓释丁丙诺啡。患者没有经历沉淀戒断，只有轻度戒断症状。
结论：这为可以提高耐受性的快速诱导策略提供了初步证据。照顾者的负担，与以前的诱导策略相比，治疗保留率。
方法：我们报告2例重症住院患者，活跃的阿片类药物使用障碍，其中我们开始使用经皮丁丙诺啡治疗超过48小时，然后给予单剂量舌下丁丙诺啡/纳洛酮，然后皮下缓释丁丙诺啡。患者没有经历沉淀戒断，只有轻度戒断症状。
结论：这为可以提高耐受性的快速诱导策略提供了初步证据。照顾者的负担，与以前的诱导策略相比，治疗保留率。
